ProCE Banner Activity

Amphiregulin as a Monitoring Biomarker for Patients With Acute GVHD

Slideset Download
Conference Coverage
Amphiregulin was validated as a biomarker for monitoring patients with life-threatening acute GVHD based on data from 2 prospective phase II trials.

Released: December 15, 2021

Expiration: December 14, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation